However, their applications in the clinic are limited, especially for solid tumors, due to the relatively low specificity and various toxicities.[11] Proteolysis targeting chimera (PROTAC) has emerged as a new and promising modality by utilizing an event‐driven mode of action, which draws inspiration from natural regulatory mechanisms and facilitates the elimination of native or degron‐tagged proteins from cells.[12] Recent studies have demonstrated that BRD4 degraders, such as dBET6, enable to effectively induce apoptosis of human lung cancer cells with higher potencies than JQ1. Here, BRD4 is linked to lung cancer.